Despite promising results in preclinical models, clinical studies evaluating the FAP inhibitory antibody sibrotuzumab (BIBH 1, Boehringer Ingelheim, Germany, a humanized version of a murine anti-human FAP mAb) were disappointing in colon cancer [97]. Here, FAP is linked to colonic neoplasm.